DARZALEX FASPRO®-based quadruplet regimen approved in the US for 1L transplant-ineligible multiple myeloma patients February 1, 2026
FDA sets draft rules for using MRD for supporting accelerated approvals in multiple myeloma January 25, 2026
TECVAYLI monotherapy demonstrates superior PFS and OS vs SOC in patients with R/R multiple myeloma January 18, 2026
TECVAYLI® plus DARZALEX FASPRO® combination selected for Commissioner’s National Priority Voucher Pilot program December 22, 2025
BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of R/R Multiple Myeloma Announced December 2, 2025
DARZALEX FASPRO® approved by FDA for patients with high-risk smoldering multiple myeloma November 10, 2025
TECVAYLI® + DARZALEX FASPRO® combination regimen significantly improves PFS and OS vs SOC October 21, 2025
Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of RRMM Announced October 7, 2025
Ph 3 EXCALIBER-RRMM Study of Iberdomide-SOC combo Demonstrated a Significant Improvement in MRD Negativity Rates in RRMM September 30, 2025
ACT appointed for POLB 001 Ph 2a Trial and supply of approved bispecific antibody drug secured at no cost September 30, 2025
100% MRD negativity seen in Ph 2 MajesTEC-5 study of TECVAYLI & DARZALEX FASPRO induction in transplant-eligible 1L multiple myeloma September 23, 2025
Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma September 23, 2025
First Patient Dosed in Ph 1 inMMyCAR Study of in vivo CAR T-cell Therapy for RRMM patients August 26, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
US FDA extends review period for Blenrep (belantamab mafodotin-blmf) in R/R multiple myeloma July 29, 2025
Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma July 29, 2025
